Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525689 | 0.84 | KDM4E (0.46) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL15762165 | 0.82 | TSHR (0.45) | TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL25485110 | 0.81 | IDO1 (0.47) | CYP4F2CYP4A11 | |
| SCHEMBL804931 | 0.81 | CYP4F2 (0.39) | MAPK1TSHRALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL10707893 | 0.78 | MAPK1 (0.47) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL30358275 | 0.77 | ALDH1A1 (0.50) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL9488681 | 0.77 | ALDH1A1 (0.50) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL14664958 | 0.77 | TP53 (0.53) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL16502247 | 0.76 | SLC7A5 (0.50) | TSHRALDH1A1SMN1; SMN2POLBGAA | |
| SCHEMBL18927002 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9683003-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MAPK1 1383/4885L3MBTL1 3060/4885TSHR 3687/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MAPK1 1383/4885L3MBTL1 3060/4885TSHR 3687/4885 |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MAPK1 1383/4885L3MBTL1 3060/4885TSHR 3687/4885 |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | MAPK1 1383/4885L3MBTL1 3060/4885TSHR 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.